Mutation and expression of TP53 in malignant melanomas
- PMID: 7597286
- DOI: 10.1007/978-3-642-78771-3_10
Mutation and expression of TP53 in malignant melanomas
Abstract
Mutations of the TP53 gene are the most common genetic alterations in human malignancies. Overexpression of the p53 protein has been reported in high frequencies in all types of skin cancer. To determine the role of TP53 in the pathogenesis of malignant melanoma, we investigated the expression of p53 in 12 cell lines and 145 primary and metastatic lesions by immunohistochemistry. Overexpression of p53 was predominantly detected in the cytoplasm of the cells in 96 (66%) tumor and 12 (93%) cell lines. In contrast to findings in other tumor types, in melanomas immunoreactive cells were found in clusters or as scattered single cells. In primary melanomas, the frequency of p53 overexpression did not correlate with tumor thickness. Nucleotide sequencing of TP53 genes of 24 melanoma tumors/cell lines demonstrated point mutations in seven samples, all coding for mutant p53 protein species. The frequency of TP53 alterations of 20%-30% is lower than in other skin tumor types. Notably, immunohistochemistry was not a suitable method to distinguish overexpression of wild-type p53 from mutant species, since cell lines/tumors with TP53 mutations did not show distinctive staining patterns. The mutation pattern in six out of seven lesions was similar to that caused by ultraviolet light damage. This finding may be regarded a further indication for a pathogenetic role of UV light damage in at least a subgroup of malignant melanomas.
Similar articles
-
Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: an update.Adv Exp Med Biol. 2014;810:208-33. doi: 10.1007/978-1-4939-0437-2_12. Adv Exp Med Biol. 2014. PMID: 25207368 Review.
-
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.Br J Cancer. 1999 Feb;79(5-6):921-6. doi: 10.1038/sj.bjc.6690147. Br J Cancer. 1999. PMID: 10070891 Free PMC article.
-
Overexpression and mutations of p53 in metastatic malignant melanomas.Int J Cancer. 1996 Jul 29;67(3):313-7. doi: 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U. Int J Cancer. 1996. PMID: 8707401
-
UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.Adv Exp Med Biol. 2017;996:27-40. doi: 10.1007/978-3-319-56017-5_3. Adv Exp Med Biol. 2017. PMID: 29124688 Review.
-
Mutation and expression of the p53 gene in malignant melanoma cell lines.Int J Cancer. 1993 Jun 19;54(4):693-9. doi: 10.1002/ijc.2910540427. Int J Cancer. 1993. PMID: 8514460
Cited by
-
Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma.Mol Clin Oncol. 2021 Dec;15(6):270. doi: 10.3892/mco.2021.2432. Epub 2021 Nov 1. Mol Clin Oncol. 2021. PMID: 34790354 Free PMC article.
-
Pharmacological Characteristics of the Hydroethanolic Extract of Acmella oleracea (L) R. K. Jansen Flowers: ADME/Tox In Silico and In Vivo Antihypertensive and Chronic Toxicity Evaluation.Evid Based Complement Alternat Med. 2023 Apr 29;2023:1278720. doi: 10.1155/2023/1278720. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 37159592 Free PMC article.
-
Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.BMB Rep. 2024 Jun;57(6):299-304. doi: 10.5483/BMBRep.2023-0246. BMB Rep. 2024. PMID: 38835116 Free PMC article.
-
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.J Exp Med. 2013 Mar 11;210(3):581-603. doi: 10.1084/jem.20121439. Epub 2013 Feb 18. J Exp Med. 2013. PMID: 23420876 Free PMC article.
-
TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma.Cancer Inform. 2023 Aug 31;22:11769351231177267. doi: 10.1177/11769351231177267. eCollection 2023. Cancer Inform. 2023. PMID: 37667731 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous